Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Scintillation Proximity Assay from US Patent US11612596: "Pharmaceutical formulations comprising CCR3 antagonists"
Assay data:10 Active, 10 Activity ≤ 1 µM, 10 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Inhibition of CCR3 (unknown origin) at 10 uM relative to control
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Antagonist activity against CCR3 (unknown origin) assessed as inhibition of beta-arrestin 2 recruitment at 10 microM by beta arrestin assay relative to control
Agonist activity against CCR3 (unknown origin) assessed as induction of beta-arrestin 2 recruitment at 10 microM by beta arrestin assay relative to control
Scintillation Proximity Assay from US Patent US8742115: "Co-crystals and salts of CCR3-inhibitors"
Assay data:35 Active, 1 Activity ≤ 1 nM, 34 Activity ≤ 1 µM, 35 Tested
Assay in WO 2010 115836 from US Patent US10213421: "Pharmaceutical formulations comprising CCR3 antagonists"
PRESTO-Tango GPCRome screening (CCR3)
SummaryRelated BioAssays by Target
Agonist activity at human CCR3 expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control
Assay data:8 Tested
Antagonist activity at human CCR3 expressed in CHO-K1 cells by PathHunter beta-arrestin assay
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Antagonist activity at human CCR3 expressed in CHO-K1 cells at 20 uM by PathHunter beta-arrestin assay relative to control
Antagonist activity at human Gi/G0-coupled CCR3 receptor expressed in CHO-K1 cells assessed as inhibition of CCL13-induced beta arrestin2 recruitment at 500 nM preincubated for 30 mins followed by CCL13 stimulation and measured after 90 to 180 mins by pathhunter assay
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Antagonist activity at CCR3 (unknown origin)
Agonist activity at CCR3 (unknown origin)
Human CCR3 (Chemokine receptors)
Assay data:29 Active, 29 Tested
Antagonist activity at human EGFP-fused CCR3 expressed in mouse L1.2 cells assessed as inhibition of CCL11-induced chemotaxis measured after 1.5 hrs by PicoGreen dsDNA reagent-based assay
Assay data:4 Active, 1 Activity ≤ 1 µM, 4 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Antagonist activity at human EGFP-fused CCR3 expressed in mouse L1.2 cells assessed as inhibition of CCL11-induced chemotaxis at 1 uM measured after 1.5 hrs by PicoGreen dsDNA reagent-based assay
Assay data:10 Active, 10 Tested
Genome-wide siRNA screen of genes regulating the Lipopolysaccharide-induced TNF-alpha response in human macrophages_Primary screen TNF readout
Assay data:2853 Active, 18113 Tested
SummaryRelated BioAssays by Same Project
Binding affinity to CCR3 receptor (unknown origin)
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on